Equities analysts expect Sarepta Therapeutics Inc (NASDAQ:SRPT) to announce earnings of ($0.47) per share for the current quarter, Zacks reports. Nine analysts have provided estimates for Sarepta Therapeutics’ earnings. The highest EPS estimate is ($0.21) and the lowest is ($1.24). Sarepta Therapeutics posted earnings per share of ($1.15) during the same quarter last year, which suggests a positive year over year growth rate of 59.1%. The company is expected to issue its next quarterly earnings report on Wednesday, July 18th.
On average, analysts expect that Sarepta Therapeutics will report full-year earnings of ($1.22) per share for the current financial year, with EPS estimates ranging from ($1.61) to ($0.90). For the next year, analysts forecast that the business will report earnings of $0.15 per share, with EPS estimates ranging from ($0.88) to $1.18. Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Sarepta Therapeutics.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Thursday, May 3rd. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.23). Sarepta Therapeutics had a negative net margin of 83.88% and a negative return on equity of 24.68%. The firm had revenue of $64.60 million for the quarter, compared to the consensus estimate of $65.31 million. During the same quarter in the prior year, the firm earned ($0.57) earnings per share. The company’s revenue for the quarter was up 295.3% compared to the same quarter last year.
Several equities research analysts have commented on the company. WBB Securities reissued a “buy” rating on shares of Sarepta Therapeutics in a report on Wednesday, June 20th. Nomura boosted their target price on Sarepta Therapeutics from $131.00 to $205.00 and gave the stock a “buy” rating in a report on Thursday, June 21st. Robert W. Baird reissued an “outperform” rating and issued a $202.00 target price (up from $120.00) on shares of Sarepta Therapeutics in a report on Thursday, June 21st. Needham & Company LLC boosted their target price on Sarepta Therapeutics from $109.00 to $204.00 and gave the stock a “buy” rating in a report on Wednesday, June 20th. Finally, SunTrust Banks boosted their target price on Sarepta Therapeutics to $176.00 and gave the stock a “buy” rating in a report on Friday, June 22nd. Four analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $147.98.
Shares of Sarepta Therapeutics traded down $0.31, hitting $137.73, during mid-day trading on Friday, according to MarketBeat. 656,496 shares of the stock traded hands, compared to its average volume of 1,646,908. The company has a quick ratio of 12.28, a current ratio of 13.37 and a debt-to-equity ratio of 0.55. Sarepta Therapeutics has a 52 week low of $32.80 and a 52 week high of $176.50. The firm has a market capitalization of $9.04 billion, a PE ratio of -83.93 and a beta of 1.34.
In other news, Director Richard Barry sold 75,000 shares of the business’s stock in a transaction on Wednesday, June 27th. The stock was sold at an average price of $130.34, for a total value of $9,775,500.00. Following the completion of the transaction, the director now owns 3,170,432 shares in the company, valued at $413,234,106.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.90% of the stock is owned by insiders.
Several hedge funds have recently bought and sold shares of the company. Clarus Wealth Advisors purchased a new stake in Sarepta Therapeutics during the second quarter valued at $124,000. Arrowstreet Capital Limited Partnership purchased a new stake in Sarepta Therapeutics during the fourth quarter valued at $217,000. Bayesian Capital Management LP purchased a new stake in Sarepta Therapeutics during the first quarter valued at $221,000. Zeke Capital Advisors LLC purchased a new stake in Sarepta Therapeutics during the first quarter valued at $241,000. Finally, ETRADE Capital Management LLC purchased a new stake in Sarepta Therapeutics during the fourth quarter valued at $247,000. Hedge funds and other institutional investors own 86.27% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.